Intercept Pharmaceuticals

Executive Summary

Intercept Pharmaceuticals, now a wholly owned subsidiary of Alfasigma S.p.A., is a biopharmaceutical company dedicated to developing and commercializing therapies for rare and serious liver diseases. Leveraging its expertise in Farnesoid X Receptor (FXR) biology, the company has established a strong foothold in hepatology, most notably through its lead product Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC). Ocaliva remains the cornerstone of Intercept's commercial efforts, providing a non-surgical option for patients with this chronic cholestatic liver disease. As part of Alfasigma, Intercept benefits from the financial and operational resources of a larger pharmaceutical group, which could accelerate pipeline development and global expansion initiatives. Looking ahead, Intercept's pipeline includes ongoing research into additional FXR agonists and combination therapies targeting liver diseases such as non-alcoholic steatohepatitis (NASH), although past clinical trials in NASH have been challenging. The company's primary near-term focus will likely be on maximizing Ocaliva's market penetration, securing regulatory approvals in new geographies, and advancing early-stage programs. While Intercept is no longer publicly traded, its progress under Alfasigma's stewardship will be closely watched by the biotech community, with potential catalysts including data readouts from clinical studies and regulatory milestones in key markets.

Upcoming Catalysts (preview)

• H2 2026Pivotal Phase 3 Trial Results for Ocaliva in PBC Combination Therapy60% success
• Q1 2027FDA Decision on Ocaliva Supplemental New Drug Application (sNDA) for Expanded Label in PBC70% success
• 2026Initial Phase 1/2 Data for Novel FXR Agonist in NASH or Other Liver Indications30% success